Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

M. Gentile, T.D. Shanafelt, F.R. Mauro, G. Reda, D. Rossi, L. Laurenti, M.I. Del Principe, G. Cutrona, I. Angeletti, M. Coscia, Y. Herishanu, A. Chiarenza, S. Molica, S. Ciolli, N. Goldschmidt, F. Angrilli, A. Giordano, A. Rago, O. Bairey, G. TripepiK.G. Chaffee, P.A. Sameer, E. Vigna, K. Zirlik, L. Shvidel, I. Innocenti, A.G. Recchia, F. Di Raimondo, G. Del Poeta, A. Cortelezzi, A. Neri, M. Ferrarini, G. Gaidano, N.E. Kay, A. Polliack, R. Foà, F. Morabito

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)703-706
Number of pages4
JournalEuropean Journal of Haematology
Volume101
Issue number5
DOIs
Publication statusPublished - 2018

Keywords

  • bendamustine
  • cyclophosphamide
  • fludarabine
  • ofatumumab
  • pentostatin
  • protein p53
  • rituximab, adult
  • aged
  • cancer combination chemotherapy
  • cancer immunotherapy
  • cancer patient
  • cancer prognosis
  • cancer risk
  • cancer survival
  • chronic lymphatic leukemia
  • Chronic Lymphocytic Leukemia International Prognostic Index
  • clinical feature
  • cohort analysis
  • female
  • follow up
  • gene mutation
  • high risk patient
  • human
  • intermediate risk patient
  • International Prognostic Index
  • Letter
  • leukemogenesis
  • low risk patient
  • major clinical study
  • male
  • overall survival
  • predictive value
  • priority journal
  • progression free survival
  • validation study

Cite this